A Randomized, Open‐Label, Single‐Dose, Parallel‐Group Bioequivalence Study of Ferric Carboxymaltose Injection Under Fasting Conditions in Chinese Adult Subjects With Iron Deficiency Anemia
Pharmacology Research & Perspectives · 2025
DOI: 10.1002/prp2.70137 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Pharmacology Research & Perspectives, 2025. Verfasst von Fengyun Gong und 3 weiteren Autor:innen. Beteiligte Einrichtung: Phase I Clinical Trial, Laboratory, Wuhan Jinyintan Hospital, Tongji Medical College of Huazhong University of Science and Technology, Hubei Clinical…. Hauptthemen laut MEDLINE: Maltose, Anemia, Iron-Deficiency, Ferric Compounds, Hematinics. Die Arbeit nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
The objectives of this study were to compare the pharmacokinetics and safety profiles of the test (T) preparation (Ferric carboxymaltose injection, BrightGene Bio‐Medical Technology Co. Ltd.) and reference (R) preparation (Ferinject, Vifor France) after intravenous injection in Chinese adult subjects with iron deficiency anemia (IDA) under fasting conditions. Conducted as a single‐center, randomized, open‐label, parallel‐group trial, the study enrolled 96 IDA patients who were randomly allocated (1:1) to receive a 500 mg intravenous dose of either the T or R preparation. Post‐dose blood samples for pharmacokinetic analysis were collected at multiple time points, while any adverse events were documented. The pharmacokinetic results showed comparable serum concentration‐time curves between the two groups. The 90% confidence intervals for the geometric mean ratios of C max , AUC 0− t , and AUC 0−∞ of total serum iron and C max , AUC 0− t of serum transferrin‐bound iron were within the predefined bioequivalence criterion of 80%–125%, indicating bioequivalence between the T and R preparations under fasting conditions. There were no significant differences in the safety profile between the two groups. This study confirmed the bioequivalence of the T and R preparations under fasting conditions, along with good safety.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Phase I Clinical Trial, Laboratory, Wuhan Jinyintan Hospital, Tongji Medical College of Huazhong University of Science and Technology, Hubei Clinical Research Center for Infectious Diseases, Wuhan Research Center for Co…
- BrightGene Bio-Medical Technology Co., Ltd., Suzhou, China.
- Department of Infectious Diseases, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
ORCID-Profile: Shengling Hu
Zitieren
APA
Gong, F., Hu, S., Yuan, J., & Song, J. (2025). A Randomized, Open‐Label, Single‐Dose, Parallel‐Group Bioequivalence Study of Ferric Carboxymaltose Injection Under Fasting Conditions in Chinese Adult Subjects With Iron Deficiency Anemia. Pharmacology Research & Perspectives. https://doi.org/10.1002/prp2.70137
Vancouver
Gong F, Hu S, Yuan J, Song J. A Randomized, Open‐Label, Single‐Dose, Parallel‐Group Bioequivalence Study of Ferric Carboxymaltose Injection Under Fasting Conditions in Chinese Adult Subjects With Iron Deficiency Anemia. Pharmacology Research & Perspectives. 2025. doi:10.1002/prp2.70137
BibTeX
@article{Gong2025,
author = {Gong, Fengyun and Hu, Shengling and Yuan, Jiandong and Song, Jianxin},
title = {A Randomized, Open‐Label, Single‐Dose, Parallel‐Group Bioequivalence Study of Ferric Carboxymaltose Injection Under Fasting Conditions in Chinese Adult Subjects With Iron Deficiency Anemia},
journal = {Pharmacology Research & Perspectives},
year = {2025},
doi = {10.1002/prp2.70137}
}
EUVIMED